Your search for bevacizumab returned 4 results

Bevacizumab-adcd 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.

Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation.